Evidence map›Paper›PMID 28179589›Full record

ArticleOncotarget2017

Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease.

Xavier Guitart, Yijuang Chern, Sergi Ferré

Open access · diamondAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.Journal of caffeine and adenosine research · 2018
    Review
  2. Emerging Roles of Nucleoside Transporters.Frontiers in pharmacology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Xavier GuitartIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Yijuang ChernIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
Sergi FerréIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD, USA.
National Institutes of Health · USNational Institute on Drug Abuse · US

Funding

Neurotransmitter Receptor Heteromers in the Striatal Spine ModuleZIADA000493 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI FERRE, SERGI · 2009 to 2025
$35.6M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Age of OnsetAnimalsAnimals, Genetically ModifiedBiomarkersBrainCarrier ProteinsCorpus StriatumDilazepDipyridamoleDisease Models, AnimalDisease ProgressionEquilibrative Nucleoside Transporter 1HumansHuntingtin ProteinHuntington DiseaseMiceADORA2A protein, humanBiomarkersCarrier ProteinsDilazepDipyridamoleEquilibrative Nucleoside Transporter 1Htt protein, ratHuntingtin ProteinReceptor, Adenosine A2ASLC29A1 protein, humanSlc29a1 protein, ratTicagreloradenosineadenosine A2A receptorENT1Huntington diseaseNeuroscience

Identifiers

PMID28179589
PMCPMC5355032
OpenAlexW2587386954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.